

Summit Program

— PERSONALIZED THERAPY FOR OPTIMAL CARE —

DAY 1 | SATURDAY 4 MAY

SESSION I : GENERAL SESSION (8:20 AM - 11:10 AM)

Chairpersons: Toh Han Chong, Singapore | Chee Cheng Ean, Singapore

- 8:20 AM - 8:30 AM** **Opening Remarks**
Toh Han Chong, Singapore
- 8:30 AM - 9:00 AM** **Keynote Lecture 1**
The evolving role of personalized GI Cancer care: Past, Present & Back to the Future
Axel Grothey, USA
- 9:00 AM - 9:30 AM** **An aerial view of 2018 in GI Cancers : What did we learn?**
Shaheenah Dawood, UAE
- 9:30 AM - 10:00 AM** **Keynote Lecture 2**
The best treatment strategy for advanced Gastric Cancer in modern era of biomarkers
Sun Young Rha, South Korea
- 10:00 AM - 10:30 AM** **Coffee Break**
- 10:30 AM - 11:10 AM** **Multidisciplinary Tumour Board I : Molecular tumour board for Upper GI Cancers**
Moderator: Axel Grothey, USA
Panelists: Sun Young Rha, South Korea | Yong Wei Peng, Singapore | Jimmy So, Singapore | Azrif Muhammad, Malaysia | Syed Akram, Bangladesh | Aru Sudoyo, Indonesia | Xiao Jian, China

SESSION II: IMMUNOTHERAPY IN GI CANCERS (11:10 AM - 12:45 PM)

Chairpersons: Toh Han Chong, Singapore | Ian Chau, UK

- 11:10 AM - 11:15 AM** **Five important questions we want to answer today!**
Toh Han Chong, Singapore
- 11:15 AM - 11:35 AM** **Immunotherapeutics in Gastric Cancer**
Keun-Wook Lee, South Korea *Session Supported by BMS*
- 11:35 AM - 11:55 AM** **Immunotherapeutics in Colorectal Cancer**
Shaheenah Dawood, UAE
- 11:55 AM - 12:15 PM** **Management of Immuno-Oncology drug related toxicities**
Ian Chau, UK
- 12:15 PM - 12:45 PM** **Multidisciplinary Tumour Board II: Using immune checkpoint inhibitors: Real world cases**
Moderator: Sun Young Rha, South Korea
Panelists: Sung Bae Kim, South Korea | Axel Grothey, USA | Matthew Ng, Singapore | Aru Sudoyo, Indonesia

Organised by

12:45 PM – 1:30 PM

Lunch Break: BAYER SATELLITE SYMPOSIUM
Patients First: Advancing the standard of care for patients
Chairperson: Kong Hwai Loong , Singapore

Boosting treatment outcomes in solid tumours with MKIs
Axel Grothey, USA

The Asian experience: Strategies to optimise systemic treatments to prolong OS in HCC
Sadahisa Ogasawara, Japan

SESSION III:

PERSONALIZING THERAPY FOR HCC (1:30 PM - 4:00 PM)

Chairpersons: Pierce Chow, Singapore | Choo Su Pin, Singapore

1:30 PM – 1:45 PM

Portending the future: How will a positive 1st line trial with check-point inhibitors in HCC change the treatment paradigm in HCC
Thomas Yau, HK

1:45 PM – 2:00 PM

Portending the future: If there were a negative 1st line trial with check-point inhibitors in HCC, what would subsequent clinical trials be like?
Stephen Chan, HK

2:00 PM – 2:15 PM

Emerging paradigms in the management of locally advanced HCC
Jens Ricke, Germany

2:15 PM – 2:30 PM

The potential for cure with resection in HCC – A metro-ticket approach
Pierce Chow, Singapore

2:30 PM – 3:00 PM

Multidisciplinary Tumour Board III: Real World Management of HCC
Moderator: Pierce Chow, Singapore
Panelists: Choo Su Pin, Singapore | David Ng, Singapore | Apoorva Gogna, Singapore | Kiat Ho Tony Lim, Singapore | Jens Ricke, Germany | Thomas Yau, HK | Stephen Chan, HK | Alfred Kow, Singapore

3:00 PM – 3:15 PM

Systemic therapy in the management of advanced HCC
Stephen Chan, HK

3:15 PM – 4:00 PM

COFFEE & MSD SATELLITE SYMPOSIUM
Advances in the management of advanced/metastatic Esophageal Cancer with Immunotherapy
Sung Bae Kim, South Korea

DAY 2 | SUNDAY 5 MAY

**SESSION IV: CONTROVERSIES IN THE MANAGEMENT OF PANCREATIC CANCER
(8:30 AM - 9:30 AM)**

Chairpersons: Shailesh Shrikande, India

8:30 AM - 9:00 AM

Debate: All patients of resectable pancreas cancer should receive neoadjuvant chemotherapy first!

YES: Goro Honda, Japan

NO : Shailesh V. Shrikhande, India

9:00 AM - 9:30 AM

Pancreatic Tumour Board- Real world management across the broad, wide, diverse lands of Asia

Moderator : Bhawna Sirohi, India

Panelists : Azrif Muhammad, Malaysia | Syed Akram, Bangladesh | Xiao Jian, China | Goro Honda, Japan | Shailesh Shrikande, India | Brian Goh, Singapore | Damien Tan, Singapore

**SESSION V: COLORECTAL CANCER : CHALLENGING CLINICAL SCENARIOS
(9:30 AM - 12:35 PM)**

Chairpersons: Iain Tan, Singapore | Aru Sudoyo, Indonesia

9:30 AM - 10:00 AM

Keynote Lecture (3)

The molecular and immune biology of Colorectal Cancer as it relates to clinical treatments: A summary of what we have learnt in the last 2 years

Sabine Tejpar, Belgium

Challenging Scenario (1) - (10:00 AM - 10:15 AM)

MSI-H CRC - It's impact on adjuvant treatment decisions, and in late stage, sequencing of immunotherapy and chemotherapy and management at progression -current data-

Kai Keen Shiu, UK

Session is supported by BMS

10:15 AM - 10:20 AM

Q & A

10:20 AM - 10:35 AM

Case Discussion:

Facilitated by Koo Si-Lin, Singapore

Panelists: Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Ian Chau, UK | Raghav Sundar, Singapore | Kai-Keen Shiu, UK

10:35 AM - 10:50 AM

Coffee Break

Challenging Scenario (2) - (10:50 AM - 11:05 AM)

Chaipersons: Clarinda Chua, Singapore | Raghav Sundar, Singapore

10:15 AM- 11:05 AM

Right-sided Colon Cancer : What is the optimal treatment sequence in right sided colon cancer for (a) conversion therapy (b) high volume disease (c) intermediate volume disease

Kentaro Yamazaki, Japan

Session is supported by Merck Serono

11:05 AM - 11:10 AM

Q & A

11:10 AM -11:25 AM

Case Discussion:

Facilitated by Yong Wei Peng, Singapore

Panelists : Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Ian Chau, UK |

Chan Chung Yip, Singapore | Alfred Kow, Singapore | Tan Wah Siew, Singapore | Clarinda Chua, Singapore

Challenging Scenario (3) - (11:25 AM - 11:40 AM)

Chaipersons: Shaheenah Dawood, UAE | Toh Han Chong, Singapore

11:25 AM - 11:40 AM

Management of synchronous Rectal Cancer in the presence of resectable distant metastases

Chee Cheng Ean, Singapore

11:40 AM - 11:45 AM

Q & A

11:45 AM - 12:00 PM

Case Discussion:

Facilitated by Tan Wah Siew, Singapore | Iain Tan, Singapore

Panelists : Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Tan Ker Kan, Singapore |

Connie Yip, Singapore | Chee Cheng Ean, Singapore | Alfred Kow, Singapore

Challenging Scenario (4) (12:00 PM - 12:15 PM)

Chaipersons: Shaheenah Dawood, UAE | Toh Han Chong, Singapore

12:00 PM- 12:15 PM

Selecting antiangiogenic agents in 1st, maintenance and beyond progression in CRC: Practical Considerations

Ian Chau, UK

Session is Supported by Lilly Oncology

12:15 PM - 12:20 PM

Q & A

12:20 PM - 12:35 PM

Case Discussion:

Facilitated by Ian Chau, UK | Chee Cheng Ean, Singapore

Panelists : Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Yong Wei Peng, Singapore

CLOSING REMARKS & LUNCH